Table 2. Univariate and multivariate analyses of progression of disease within 24 months.
| Cumulative incidence of progression of disease within 24 months | |||
|---|---|---|---|
| Univariate P value |
Multivariate | ||
| Hazard ratio (95%CI) | P value | ||
| Age | |||
| <70 years | 0.032 | reference | 0.15 |
| ≥70 years | 3.72 (0.63–21.93) | ||
| Sex | |||
| Male | 0.51 | - | - |
| Female | - | ||
| PS | |||
| 0–1 | 0.11 | - | - |
| 2–4 | - | ||
| Clinical stage | |||
| Limited | 0.67 | - | - |
| Advanced | - | ||
| WBC | |||
| <9,000 U/mL | 0.35 | - | - |
| ≥9,000 U/mL | - | ||
| LDH | |||
| <220 U/L | <0.001 | reference | 0.39 |
| ≥220 U/L | 2.41 (0.31–18.25) | ||
| sIL-2R | |||
| <1,700 U/mL | 0.002 | reference | 0.25 |
| ≥1,700 U/mL | 4.52 (0.34–59.81) | ||
| Blastoid variant | |||
| Non-blastoid variant | 0.01 | reference | 0.018 |
| Blastoid variant | 7.21 (1.39–37.32) | ||
| Ki67 index | |||
| <30% | 0.57 | - | - |
| ≥30% | - | ||
PS, performance status; WBC, white blood counts; LDH, lactate dehydrogenase; sIL2-R, soluble interleukin-2 receptor; 95%CI, 95% confidence interval.